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Abstract
Background—In recent years, there has been an increase in emergence and use of novel 
psychoactive substances (NPS) in the US and worldwide. However, there is little published 
epidemiological survey data estimating the prevalence of use in the US.
Method—Data on self-reported NPS use came from the National Survey of Drug Use and Health 
(2009–2013), a national representative sample of non-institutionalized individuals in the US. 
Subjects were asked to provide names of (non-traditional) drugs they used that they were not 
specifically asked about. We examined lifetime prevalence and sociodemographic correlates of 
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self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12–34-years-
old.
Results—1.2% of subjects self-reported any use of the 57NPS we examined. Use of psychedelic 
tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 
2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 
2009–2013 and use was most common among males, whites, older subjects, those of lower 
income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, 
cocaine, ecstasy/MDMA) was highly prevalent among NPS users.
Conclusion—This the first study reporting on use of a variety of NPS in a nationally 
representative US sample; however, use appears to be underreported as other national data suggest 
higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and 
systematically assessing NPS use would allow researchers to ask about hundreds of NPS and 
improve reporting as new drugs continue to rapidly emerge.
Keywords
novel psychoactive substances; novel psychoactive drugs; phenethylamines; tryptamines; 
synthetic cannabinoids; synthetic cathinones
1. INTRODUCTION
Novel psychoactive substances (NPS) have been emerging in the US and worldwide at an 
unprecedented rate. In 2009, the US National Forensic Laboratory Information System 
(NFLIS)received drug identification reports of two synthetic cannabinoids and four 
synthetic cathinones (Senate Caucus on International Narcotics Control, 2013). By 2012, 
NFLIS received reports on 57 different synthetic cannabinoids and 31 synthetic cathinones. 
In Europe, 101NPS were discovered in 2014, up from 73 in 2012, 49 in 2011 and 41 in 
2010(European Monitoring Centre for Drugs and Drug Addiction [EMCDDA], 2012, 2015). 
Globally, 348 NPS were reported by December 2013 to the United Nations Office on Drugs 
and Crime (UNODC), up from 166 in 2009(UNODC, 2014).
NPS are often sold as “research chemicals,” “plant food” or “bath salts,” labeled “not for 
human consumption,” and are sold over the Internet, in head shops, or by street dealers. 
These (often “legal”) drugs tend to be synthetic derivatives or analogues of older, more 
traditional drugs such as cannabis (marijuana), ecstasy (3,4-
methylenedioxymethamphetamine [MDMA]), amphetamine, and lysergic acid diethylamide 
(LSD). Such drugs usually become controlled, but replacement drugs with similar chemical 
structures are often created to continue to evade law enforcement (Cohen, 2014; Khazan, 
2013).
There are hundreds of NPS and many can be classified into somewhat distinct categories. 
One of the largest stimulant classes that contain many NPS is the phenethylamine class, 
which includes synthetic cathinones (commonly referred to as “bath salts”), empathogenic 
stimulants (e.g., N-methyl-1,3-benzodioxolylbutanamine; MBDB), and new psychedelics 
(e.g., 2C or NBOMe series drugs; Hill and Thomas, 2011). There are also many other 
stimulant NPS (e.g., piperazines), new synthetic dissociative drugs (e.g., methoxetamine 
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[MXE], which mimics ketamine), and other psychedelics similar to LSD. Synthetic 
cannabinoids, which mimic Δ-9-tetrahydrocannabinol (THC), the main psychoactive 
component in cannabis, have gained prevalence at a fast pace since 2008 (EMCDDA, 2015).
In recent years, numerous case reports and systematic reports from poison centers and 
forensic laboratories have been published to alert the medical community about rates of 
reported poisonings and associated adverse outcomes associated with NPS use (Dart et al., 
2015; Elliott and Evans, 2014; Forrester, 2013, 2014; Hill et al., 2014; Murphy et al., 2013; 
Vazirian et al., 2015). However, epidemiologic survey data is sorely needed from 
representative samples to estimate prevalence of NPS use generally, as well as use of 
specific NPS or classes of NPS.
While population surveys tend to assess self-reported use of various “traditional” 
psychoactive drugs (e.g., cocaine), very few national surveys ask about use of newer, less 
traditional drugs. Some European surveys such as the Crime Survey for England and Wales 
started asking about mephedrone and benzylpiperazine (BZP)in 2010 (United Kingdom 
Focal Point on Drugs, 2014) and the Monitoring the Future (MTF) study, a US national 
representative sample of adolescents in high schools, started asking students about synthetic 
cannabinoids in 2011 and “bath salts” in 2012 (Miech et al., 2015). However, there are now 
hundreds of new (or uncommon) psychoactive drugs that are not systematically assessed in 
these surveys.
According to NFLIS data on NPS cases analyzed by federal, state, and local forensic 
laboratories, there were 469 reports of synthetic cannabinoids in the first half of 2010, 
23,123 reports in the first half of 2012, and 19,838 in the first half of 2014(US Drug 
Enforcement Administration [DEA], 2014). Reported poisonings involving synthetic 
cannabinoids have skyrocketed in the US with poisonings increasing 330% in the first 
quarter of 2015(Law et al., 2015). With respect to synthetic cathinones (a.k.a.: “bath salts”), 
reports to NFLIS increased from 142 in the first half of 2010 to 7,997 in the first half of 
2013 (US DEA, 2014). National and state-specific (e.g., Texas, North Carolina) Poison 
Control Center data also suggest that use of NPS is on the rise (Dart et al., 2015; Forrester, 
2013, 2014; Murphy et al., 2013).
MTF national survey data suggest that about 10% of high school seniors in the US (modal 
age: 18) have used synthetic cannabinoids and 1% have used “bath salts” in the last 12 
months (Miech et al., 2015; Palamar and Acosta, 2015). Indicator data presented by the 
Community Epidemiology Work Group (CEWG) in the US suggests that synthetic 
cannabinoids and cathinones appear to be the most prevalent NPS in the US; but there are 
mixed patterns throughout US cities (CEWG, 2014). Rates of use of psychedelic 
phenethylamines (e.g., 2C-I) have begun to increase in some US cities as well. However, 
such indicator data tends to rely on reported poisonings, arrests, seizures, and treatment 
admissions. Few surveys or assessments ask about use of specific new drugs, so indicator 
data does not always detect increasing rates of use. Some Internet surveys have focused on 
users of specific NPS(Carhart-Harris et al., 2011; Johnson and Johnson, 2014), other surveys 
have focused on individuals at high risk for use (e.g., nightclub attendees; Kelly et al., 
2013), and every year the Global Drug Survey (this year taken by users in over 50 countries) 
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asks thousands of club-goers about use of dozens of NPS(Barratt et al., 2014; Morley et al., 
2015; Uosukainen et al., 2015; Winstock et al., 2015; Winstock and Barratt, 2013; Winstock 
et al., 2014).
While studies of targeted samples have begun to provide rates of use of NPS in high-risk 
populations (e.g., club-goers), there are little to no data on these drugs from general US 
population samples. We utilized data from the National Survey on Drug Use and Health 
(NSDUH), which does not ask specifically about NPS, but allows subjects to enter names of 
NPS. While this method is limited, this feature helps provide much needed data as national 
surveys are currently lacking standard questions about NPS. We also delineated 
sociodemographic and other drug use correlates of use of NPS to inform prevention among 




Data came from the five most recent cohorts (2009–2013) of NSDUH, an ongoing cross-
sectional survey of non-institutionalized individuals in the 50 US states and District of 
Columbia (Substance Abuse and Mental Health Services Administration [SAMHSA], 2014). 
NSDUH is a nationally representative probability sample of populations living in 
households obtained through four stages: first, census tracts (subdivisions of counties that 
are the primary sampling units in the NSDUH survey design) were selected within each 
state; then, segments (one or more blocks or streets) in each tract were selected; then 
dwelling units were selected, and finally, respondents were selected.
Surveys were administered through computer-assisted interviewing (CAI) conducted by an 
interviewer and audio computer-assisted self-interviewing (ACASI). For the CAI, field 
interviewers administered a computer-based survey to respondents. The CAI collected all 
core variables. For the ACASI, respondents were provided with a computer and headphones 
and asked to complete the survey; field interviewers were trained to not look at the screens 
while the ACASI was being administered in order to maintain privacy and confidentiality, 
and to increase honest reporting (Butler et al., 2012). The ACASI collected noncore 
variables including the NPS data reported here (LeBaron and Dean, 2010).
NSDUH provided sampling weights to address unit- and individual-level non-response. 
Weights were adjusted to ensure estimates are consistent with estimates provided by the US 
Census Bureau. Since this analysis utilized aggregated data from five cohorts (to increase 
sample size), weights were divided by 5 (the number of combined datasets). Further 
information on sampling and survey techniques can be found elsewhere (SAMHSA, 2014). 
We aggregated data from all cohorts and examined data for individuals, ages 12–34 
(N=212,123). The weighted interview response rates for 2009, 2010, 2011, 2012, and 2013 
were 75.6%, 74.6%, 74.4%, 73.0%, and 71.7%, respectively.
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Subjects were asked whether they had ever used a variety of (“traditional”) drugs. NSDUH 
did not ask about specific NPS; however, after being asked about hallucinogens (e.g., LSD), 
subjects were then asked: “Have you ever, even once, used any other hallucinogens besides 
the ones that have been listed?” Those who answered “yes” were told: “Please type in the 
name of the other hallucinogens you have used.” Subjects were able to list up to five drugs. 
NSDUH provided five variables in its public dataset, each containing coded drug name 
response categories (containing the number of subjects who typed that NPS name in); e.g., 
category response #6185 was labeled “25I-NBOMe, 2C-I-NBOMe, BOM-CI, Cimbi-5” to 
indicate that the subject typed in the name of this particular NBOMe drug. A small number 
of mentions of NPS (n=31) were also extracted from similar questions where subjects were 
asked to type in drug names of drugs (not asked about specifically beforehand) for 
nonmedical use of stimulants, other inhalants, or other drugs they have injected. The only 
NPS systematically asked about by NSDUH were use of a subclass of tryptamines via the 
following question: “Have you ever, even once, used any of the following: DMT, also called 
dimethyltryptamine, AMT, also called alpha-methyltryptamine, or Foxy, also called 5-MeO-
DIPT?” Responses to this item were included in our indicator variables representing use of 
1) any NPS, and 2) the specific tryptamine class. Survey questions and information on 
survey skip-patterns are presented in Supplementary Table 11.
We chose to examine synthetic drugs reported to NSDUH that were either “new” or 
“uncommon” (e.g., non-traditional synthetic psychoactive drugs). We chose to include 
“uncommon” to our criteria because there is currently no standard definition for “new” or 
“novel” drugs (King et al., 2014). Similarly, while some synthetic drugs are in fact “new” 
(e.g., the NBOMe series), others such as the 2C series are often seen as “new,” even though 
use has been reported for well over a decade. Other drugs were discovered decades ago and 
are either uncommon or have re-emerged in recent years. MDA, for example, was 
discovered over a century ago, but use is not common (as is MDMA). We ultimately chose 
to include 57 synthetic drugs reported to NSDUH for analysis (listed in Supplemental Table 
22). We then collapsed data for all subjects (all five years) into a single cross-section, and 
collapsed all NPS responses into a single variable indicating whether subjects self-reported 
use of any NPS. We then categorized all 57 drugs into categories (and subcategories) with 
categorization guided by government reports (e.g., EMCDDA, NFLIS) and popular websites 
that discuss these drugs including Erowid, BlueLight, and Wikipedia.
We also created a three-level variable indicating whether each subject used: 1) no illicit drug 
or NPS, 2) an illicit drug, but not an NPS, or 3) an NPS and an illicit drug. All but 26 
subjects who reported use of NPS reported use of any other illicit drug. For consistency, 
these 26 subjects were omitted from the variable.
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
2Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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We examined subject sex, race (i.e., white non-Hispanic, black non-Hispanic, Hispanic, 
other race), employment status, educational attainment, annual family income, and marriage 
status. We also examined population density, which was measured in terms of metropolitan 
statistical areas (MSAs).
2.4. Analyses
We first examined descriptive statistics to determine the prevalence of self-reported use of 
NPS overall and in each category. We then computed Χ2 statistics to determine whether 
there were significant differences according to use of any NPS with regard to each covariate. 
We then replicated these bivariable analyses focusing on the three NPS categories that were 
most prevalent.
Using the three-level variable as the outcome, we then examined correlates of use of 1) an 
illicit drug, but not an NPS and 2) an illicit drug and an NPS, in comparison to those who 
reported use of neither. This was done to examine whether NPS users were similar to non-
NPS-illicit drug users in comparison to those who used neither. Results were modeled using 
multinomial logistic regression. We first examined associations of each covariate with both 
outcome categories (compared to those who reported no use) in a bivariable manner 
(without controlling for other covariates). We then examined all covariates simultaneously 
in the same multivariable model. Thus, in the bivariable models each covariate was 
associated with an odds ratio (OR) and adjusted ORs (AORs) were produced in the single 
multivariable model. No statistical correction was utilized for multiple testing and all 
analyses were weighted to account for the complex sample design and analyzed using Stata 
SE 13 (StataCorp, College Station, TX, 2009), which used the Taylor series estimation 
methods in order to provide accurate standard errors (Heeringa et al., 2010). This secondary 
data analysis deemed exempt by the New York University Langone Medical Center 
Institutional Review Board.
3. RESULTS
A total of 2,423 subjects (1.2%)self-reported use of any NPS (Table 1). The most common 
classes of drugs reported were tryptamines, psychedelic phenethylamines, and synthetic 
cannabinoids. The 2C subclass of psychedelic phenethylamines was the most prevalent 
subclass.
Table 2 presents sample descriptives and results of bivariable analyses by overall NPS and 
by the three most common classes of NPS. Males, whites, subjects age 18–25, and those 
residing in MSAs (especially large MSAs), or who were employed full-time, had some 
college education, or were not married, were at highest risk for NPS use. Lifetime use of 
each drug was robustly associated with increased risk of using an NPS (all ps<.001). Almost 
all (≥95%) subjects who used an NPS also reported lifetime use of alcohol, marijuana, or 
cigarettes, and lifetime use of ecstasy (79.4%), opioids (79.1%), cocaine (74.3%), and LSD 
(73.7%)were also common. Regarding analyses of NPS subclasses, results tended to be 
similar to overall use of NPS, but there were some notable differences across categories. Use 
of synthetic cannabinoids appeared to be much higher (26.8%) among 12–17-year-olds, 
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compared to the other two categories, which were used by only 4.6–7.2% of those in this age 
group. Similarly, use of synthetic cannabinoids does not appear to be as rare among females, 
Hispanics, or among those in small MSAs compared to other categories. In addition, use of 
various other drugs among users of synthetic cannabinoids tended to be rarer in comparison 
to those who used drugs from other classes; however, this might be a function of age as 
many synthetic cannabinoid users were young and possibly not yet exposed to as many other 
drugs.
Finally, Table 3 presents results of the multinomial models. Compared to use of other illicit 
drugs, NPS use has increased in recent years, particularly in 2013. Older subjects were at 
higher risk for NPS use, as were those residing in cities and those with some college. Racial 
minorities and married individuals were also at low risk for reporting use of NPS. These 
significant findings were not only compared to those who reported no use of drugs, but also 
compared to those who reported use of any other illicit drugs.
4. DISCUSSION
This the first study reporting on self-reported use of a variety of NPS in a nationally 
representative US sample. Results suggest that about one out of 100 (1.2%) subjects self-
reported any use of the 57NPSexamined. Self-reported use of tryptamines (primarily DMT) 
was most common (reported by 86.1% of NPS users), followed by use of psychedelic 
phenethylamines and synthetic cannabinoids. We present prevalence and correlates of self-
reported use of NPS and some specific NPS classes, but results suggest that the method of 
assessing NPS use led to (possibly severe) levels of underreporting.
The only other nationally representative US survey that asks about NPS use is MTF, which 
assesses last 12-month use of synthetic cannabinoids and “bath salts.” In MTF, 1% of high 
school seniors (modal age: 18) report last-year use of “bath salts” and about 10% have 
reported use of synthetic cannabinoids (Palamar, 2015; Palamar and Acosta, 2015). 
Therefore, it appears that synthetic cannabinoid use is being underreported to NSDUH, as 
there is no specific question asking about use. NSDUH only asks specifically about use of 
DMT/AMT/Foxy, and DMT happened to be the most prevalent NPS reported. While we do 
not doubt the prevalence of DMT use, we do believe that use of many other NPS (e.g., 
synthetic cannabinoids) is severely underreported as subjects are not specifically asked 
about use. Thus, we believe we discovered a bias in which self-reported use of DMT was the 
most reported NPS solely because it was the only NPS systematically assessed by NSDUH. 
Past ketamine prevalence helps confirm this bias. Ketamine was used by 1.6% of high 
school seniors in 2005 (Miech et al., 2015), but NSDUH only received 78 mentions of 
ketamine use that year via the type-in option (SAMHSA, 2013a). However, in 2006, the first 
year NSDUH specifically asked about ketamine, prevalence was 1.27% (N=700; SAMHSA, 
2013b), suggesting that extreme underreporting occurred prior to asking specifically about 
ketamine.
Prevalence of use of NPS in this study differed not only from MTF results, but also from 
other surveillance studies (e.g., NFLIS), which have largely focused on poisoning data or 
seizure data from law enforcement. From January through June of 2014, NFLIS (US DEA, 
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2015)received drug identification reports of 19,838 cases revealing synthetic cannabinoids 
and 14,770 reports of (new) phenethylamines; however, the number of cases involving 
tryptamines was much lower. In fact, between 2006 and 2010, NFLIS(US DEA, 2012) only 
received 1,302 reports involving tryptamines. Similarly, a Swedish study focusing on NPS 
found that reported poisonings associated with synthetic cannabinoids were most common, 
followed by poisonings by synthetic cathinones (Helander et al., 2013). A study in the UK 
also found that synthetic cathinones (particularly mephedrone) were most commonly 
associated with reported poisonings, followed by piperazines (e.g., BZP), “miscellaneous” 
compounds (e.g., synthetic cannabinoids), and tryptamines (Elliott and Evans, 2014). 
Interesting, our study found self-report of stimulants (synthetic cathinones) to be rare 
compared to other NPS.
Despite the limitation of underreporting due to survey design, our study did corroborate 
correlational results from other studies. Consistent with other literature (CEWG, 2014; 
Elliott and Evans, 2014; EMCDDA, 2015; Wood, 2013), prevalence of NPS use increased 
between 2009 and 2013. We also confirmed that males and young adults are at highest risk 
for use of various NPS(Forrester, 2013; Helander et al., 2013; Murphy et al., 2013; Van 
Hout and Brennan, 2011; Vazirian et al., 2015). However, results were not as robust within 
the synthetic cannabinoid subgroup with slightly fewer males and more adolescents 
reporting use than did for other subgroups. Adding to previous studies, we also found that 
NPS users tended to have also used various other illicit drugs (Carhart-Harris et al., 2011; 
Elliott and Evans, 2014; Helander et al., 2013; Murphy et al., 2013). This adds to previous 
evidence that multi-drug use is common among NPS users just as it is among “club drug” 
users (Halkitis et al., 2007). Interestingly, rates of other drug use were different among 
synthetic cannabinoid users compared to users of psychedelic phenethylamines and 
tryptamines. Specifically, rates of multidrug use tended to be lower among synthetic 
cannabinoid users. Thus, synthetic cannabinoid users may have different reasons for use 
than users of other NPS, and these differences might also have to do with availability or 
shared determinants of “natural” marijuana use.
Results also suggest that NPS use appears to be more prevalent in large cities; although 
synthetic cannabinoid use appears to be more prevalent in smaller cities. Research is needed 
to determine whether high rates of use of synthetic cannabinoids in smaller cities are related 
to local marijuana policies. We also found that NPS users are more likely to be employed 
(full-time) and/or college-educated; however, again, this did not apply to synthetic 
cannabinoid users and these users were also more likely to report lower income. Therefore, 
it appears that synthetic cannabinoid use is a “different animal” compared to other NPS. 
Adding to our hypothesis that synthetic cannabinoids is a “different animal,” we found that 
white individuals were more likely to report any NPS use; however, over a quarter (27%) of 
synthetic cannabinoid users identified as Hispanic (compared to 7–10% for other 
subgroups). It may be that racial minorities are using this “legal” synthetic version of THC 
to evade arrest because racial minorities are at highest risk for arrest related to marijuana 
possession (American Civil Liberties Union, 2013; Golub et al., 2007; Johnson et al., 2008; 
Palamar, 2014; Palamar et al., 2014).
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Aside from the limitations previously discussed, it should be noted that NSDUH does not 
survey active military personnel, homeless individuals (not in shelters), or residents of 
institutional group quarters, including jails or hospitals. We did not correct for proportions 
within variables, but data were nationally representative. For each drug class (e.g., 
“hallucinogens”), subjects were only able to list up to five “other” drugs not asked about. As 
a result, some subjects who used more than five drugs may have been forced to underreport 
use; however, <1% of users reported using five NPS or NPS classes.
While many investigations focus solely on what they consider NPS, there is no standard 
definition for “new” or “novel” (King et al., 2014). For example, many drugs were 
discovered decades ago, but did not become prevalent until recently. DMT has been a 
popular drug for decades, but NSDUH combined it with two similar and newer synthetic 
drugs (AMT and Foxy) so we were unable to disaggregate DMT use; therefore, we simply 
categorized all drugs as “NPS.”
We did not consider mentions of drugs that are not synthetic that happen to contain drugs 
that are often synthetically produced. For example, we intentionally omitted ayahuasca even 
though it contains a natural form of DMT. We also did not include salvia divinorum and we 
did not include d-lysergic acid amide (LSA) as it is often (but not always) derived from 
natural and not synthetic sources. It is also unlikely that many subjects were sophisticated 
enough to know the chemical names of all drugs they have used in their lifetime. Moreover, 
it is not uncommon—especially with “Molly,” which is marketed as pure MDMA powder—
for drugs to contain NPS as adulterants (Mohr et al., 2015). So it is possible that some 
subjects who used drugs such as ecstasy did in fact unintentionally use drugs NPS as “bath 
salts.” Finally, the main outcome (lifetime NPS use) was relatively rare (1.2%) as were the 
subgroups we examined, but we still found many robust and highly significant associations.
Fundamentally, these limitations likely result in misclassification of the outcome. NPS use 
appears to be severely underestimated in this sample. There also is the possibility of 
misclassification among drugs with similar effects. Without pill or powder testing, it is often 
impossible for NPS users to accurately report the specific drugs they have taken; rather users 
usually report what they have been told they were sold. We must also keep in mind that 
poisonings and seizures do not necessarily reflect prevalence of use as each drug is 
associated with its own risk of poisoning and legal sanctions. Likewise, such indicator data 
may not always accurately reflect rates of use because drug users are a “hidden population” 
and users tend to remain unrecognized unless they are hospitalized or arrested (National 
Institute on Drug Abuse, 2006).
4.2. Conclusions
This was the first study to examine self-reported use of a variety of NPS in a nationally 
representative US sample. About one out of 100 subjects self-reported use within their 
lifetime and we believe this is an underestimation. While this nationally representative study 
was able to acquire valuable information on use of various NPS, new drugs are emerging at 
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a rapid rate (hundreds in the last few years) and we risk underreporting when subjects are 
not asked about specific new drugs (or drug classes) in a systematic manner.
Asking subjects if they have used “other” hallucinogens, stimulants, inhalants, or whether 
they have injected “other” drugs does not appear to adequately detect NPS use. We realize 
that NSDUH did not specifically intend to systematically detect NPS use, and NSDUH does 
not report on prevalence of NPS in reports, but NPS data is becoming increasingly 
important. NSDUH also did not begin asking about ketamine, GHB, or DMT until 2006, 
when use was already prevalent for many years. “Molly” use has also been prevalent and 
problematic in the US for years and MTF did not add it to the definition of ecstasy until 
2014 (Miech et al., 2015) and NSDUH has just added it to its 2015 survey (Federal Register, 
2014). Timely inclusion of new drugs is essential in order for researchers to examine 
correlates of use to help prevent epidemics. Standard questions are needed for many drugs 
(or drug classes). We believe this can be accomplished by asking about a specific drug class 
(e.g., “bath salts”) and listing NPS in that class (e.g., “Flakka”). If the subject answers 
affirmatively, then follow-up questions would be asked for specific drugs. Surveys can 
provide options to type in names of NPS (provided back-end coding of misspellings and 
street names is in place), but programming can be informed by annual/semi-annual reports 
published by NFLIS and EMCDDA. Thus, an updated and adaptable survey tool, which 
asks about various NPS and/or NPS classes would prevent underreporting and allow us to 
detect use of new drugs in a timely manner.
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1.2% of individuals in the US, age 13–34, reported use of a novel psychoactive 
substance
Use of tryptamines was most common, followed by psychedelic phenethylamines
Use increased from 2009 through 2013 and use of other illicit drugs was common
Males, whites and older or unmarried subjects were more likely to report use
An adaptable survey tool would improve reporting as new drugs continue to emerge
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